Estimation of plasma levels of warfarin and 7-hydroxy warfarin by high performance liquid chromatography in patients receiving warfarin therapy

被引：19

作者：

Kumar, Dhakchinamoorthi Krishna ^{[1
]}

Shewade, Deepak Gopal ^{[1
]}

Parasuraman, Subramani ^{[1
]}

Rajan, Sundaram ^{[1
]}

Balachander, Jayaraman ^{[2
]}

Chandran, B. V. Sai ^{[3
]}

Adithan, Chandrasekaran ^{[1
]}

机构：

[1] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Pharmacol, Pondicherry 605006, India

[2] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Cardiol, Pondicherry 605006, India

[3] Jawaharlal Inst Postgrad Med Educ & Res JIPMER, Dept Cardiothorac & Vasc Surg, Pondicherry 605006, India

来源：

JOURNAL OF YOUNG PHARMACISTS | 2013年 / 5卷 / 01期

关键词：

Carbamazepine; Metabolic ratio; Plasma concentration; Warfarin; 7-Hydroxy warfarin;

D O I：

10.1016/j.jyp.2013.02.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Warfarin is one of the most commonly prescribed oral anticoagulant for prevention of thromboembolic events. The effect of this drug is measured by monitoring prothrombin time expressed as International Normalized Ratio (INR). In some cases, however, the measurement of plasma concentration of warfarin was emphasized. In the present study, reversed phase high performance liquid chromatography (HPLC) was used to estimate the plasma drug levels. A total of 185 patients were enrolled in this study. Five milliliter of venous blood was collected using sodium EDTA tubes for pharmacokinetic analysis. Solid phase extraction was used to recover the warfarin and it's metabolite from plasma using isopropanol and potassium phosphate buffer (40: 60) mobile phase. Warfarin, 7-hydroxy warfarin and carbamazepine (internal standard) were separated on a C18 column and had the retention time 3.6 min, 2.9 min and 5.9 min, respectively. The assay was linear in warfarin concentration ranges of 0.1-5 mu g/ml. The extraction recovery was found to be similar or equal to 85%. The mean plasma concentrations of warfarin and 7-hydroxy warfarin were found to be 3.47 +/- 1.87 (SD) mg/ml, 1.25 +/- 0.81 (SD) mg/ml, respectively. Through the present study the plasma concentrations of warfarin, 7-hydroxy warfarin and their metabolic ratio was determined. The assay was sensitive to follow warfarin pharmacokinetics in a patient with warfarin therapy for 3 months and above. Copyright (C) 2013, InPharm Association, Published by Reed Elsevier India Pvt. Ltd. All rights reserved.

引用

页码：13 / 21

页数：9

共 24 条

[1] Impact of Genetic Polymorphisms and Drug-Drug Interactions on Clopidogrel and Prasugrel Response Variability [J].

Ancrenaz, V. ;

Daali, Y. ;

Fontana, P. ;

Besson, M. ;

Samer, C. ;

Dayer, P. ;

Desmeules, J. .

CURRENT DRUG METABOLISM, 2010, 11 (08) :667-677

[2] Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies [J].

Angiolillo, D. J. ;

Gibson, C. M. ;

Cheng, S. ;

Ollier, C. ;

Nicolas, O. ;

Bergougnan, L. ;

Perrin, L. ;

LaCreta, F. P. ;

Hurbin, F. ;

Dubar, M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (01) :65-74

[3]

Armstrong A. W., 2011, PRINCIPLES PHARM PAT, V3rd, P372

[4] ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [J].

Bhatt, Deepak L. ;

Scheiman, James ;

Abraham, Neena S. ;

Antman, Elliott M. ;

Chan, Francis K. L. ;

Furberg, Curt D. ;

Johnson, David A. ;

Mahaffey, Kenneth W. ;

Quigley, Eamonn M. ;

Harrington, Robert A. ;

Bates, Eric R. ;

Bridges, Charles R. ;

Eisenberg, Mark J. ;

Ferrari, Victor A. ;

Hlatky, Mark A. ;

Kaul, Sanjay ;

Lindner, Jonathan R. ;

Moliterno, David J. ;

Mukherjee, Debabrata ;

Schofield, Richard S. ;

Rosenson, Robert S. ;

Stein, James H. ;

Weitz, Howard H. ;

Wesley, Deborah J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1502-1517

[5] Pharmacokinetic drug interaction profiles of proton pump inhibitors [J].

Blume, Henning ;

Donath, Frank ;

Warnke, Andre ;

Schug, Barbara S. .

DRUG SAFETY, 2006, 29 (09) :769-784

[6] Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel? Results From the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial [J].

Good, Christopher W. ;

Steinhubl, Steven R. ;

Brennan, Danielle M. ;

Lincoff, A. Michael ;

Topol, Eric J. ;

Berger, Peter B. .

CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (01) :77-81

[7] Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition [J].

Gremmel, Thomas ;

Steiner, Sabine ;

Seidinger, Daniela ;

Koppensteiner, Renate ;

Panzer, Simon ;

Kopp, Christoph W. .

HEART, 2010, 96 (03) :186-189

[8] The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response [J].

Harmsze, Ankie M. ;

Robijns, Karen ;

Van Werkum, Jochem W. ;

Breet, Nicoline J. ;

Hackeng, Christian M. ;

ten Berg, Jurrien M. ;

Ruven, Hendrik J. T. ;

Klungel, Olaf H. ;

de Boer, Anthonius ;

Deneer, Vera H. M. .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (05) :920-925

[9] Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes [J].

Hollenberg, PF .

DRUG METABOLISM REVIEWS, 2002, 34 (1-2) :17-35

[10] Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation - A new drug-drug interaction [J].

Lau, WC ;

Waskell, LA ;

Watkins, PB ;

Neer, CJ ;

Horowitz, K ;

Hopp, AS ;

Tait, AR ;

Carville, DGM ;

Guyer, KE ;

Bates, ER .

CIRCULATION, 2003, 107 (01) :32-37

← 1 2 3 →